03:46 PM EST - Avivagen Inc. : Announced a project to establish proof-of-concept for a first human health application of its technology. The project will evaluate the efficacy of OxC-beta Technology in an established research model of an infectious disease of humans. Work will be conducted by NRC experts at its facilities based upon a jointly developed protocol and is expected to be completed in 2017. Avivagen Inc.
shares V.VIV are trading up $0.005 at $0.12.
